As the coronavirus pandemic prompts cancellations of scientific meetings around the world and shifts to virtual settings, we have been working on alternative methods to keep you informed of advances […]
Pharma companies racing to accelerate drug discovery for chronic liver diseases, such as NASH and fibrosis, need better preclinical testing tools for compound screening and mechanistic studies. Here's how next-generation […]
In honor of the inaugural International NASH Day, Insphero explains why we need better preclinical models for non-alcoholic steatohepatitis (NASH) disease drug discovery. Non-alcoholic fatty liver disease (NAFLD) is one of […]